Fosamprenavir for reflux-related throat inflammation
Part of Digestive system, Lungs & breathing clinical trials.
This Phase 2 study tests whether fosamprenavir can reduce inflammation and enzyme activity in the throat area for people with laryngopharyngeal reflux (LPR). If you still have LPR symptoms despite 3 months of twice-daily reflux medicine, this trial may offer another treatment approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older
- You have a diagnosis of LPR, confirmed by throat testing (MII-pH test shows at least one reflux event near the throat)
- Your symptom scores are high (RSI over 13 and RFS over 7)
- You tried twice-daily PPI reflux medicine for 3 months and it didn’t fully help
- You can attend clinic visits that include flexible throat scope and repeated MII-pH testing at least 3 months apart
- Your liver and safety blood tests are normal for the study screening period (if continuing from an earlier step)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well omeprazole (a common acid-blocking medicine) works for people with laryngopharyngeal reflux (LPR), a condition where stomach acid irritates the throat. If you have had throat symptoms for more than 8 weeks and are already scheduled for an endoscopy with acid monitoring, you may qualify to see if this medicine helps more than a placebo.
This trial tests whether an oral medication called fosamprenavir can help with heartburn that isn't fully controlled by standard acid-reducing pills. If you have persistent heartburn despite treatment, this study may offer a new option.
This study looks at the “upward reflux” that can irritate the throat and sometimes worsen symptoms like cough or asthma. It aims to understand the mechanisms that prevent or allow throat reflux, which may lead to better ways to manage symptoms.
This trial tests a new medicine called anaprazole for people with moderate to severe reflux esophagitis (chronic heartburn and damage to the food pipe). It compares anaprazole to a standard treatment to see which works better and is safer.
This trial tests vonaprazan (two doses) against esomeprazole to see which better heals moderate-to-severe reflux esophagitis (a damaged esophagus from acid reflux) in 8 weeks. You may qualify if you have had heartburn or regurgitation for at least a month and your doctor found grade B, C, or D damage on an endoscopy.
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
Hear when a new Laryngopharyngeal Reflux trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.